Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hypoglycemia during a treatment with interferon-alpha]

N Isambert, B Coudert, G Jolimoy

    Presse Medicale (Paris, France : 1983)
    |May 31, 1997
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Corrigendum to "Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)": [Ann Oncol 26 (2015) 2168-2173].

    Annals of oncology : official journal of the European Society for Medical Oncology·2025
    Same author

    Improved nationwide survival of sarcoma patients with a network of reference centers.

    Annals of oncology : official journal of the European Society for Medical Oncology·2024
    Same author

    Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years.

    European journal of cancer (Oxford, England : 1990)·2023
    Same author

    Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study.

    ESMO open·2023
    Same author

    MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors.

    ESMO open·2022
    Same author

    Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors.

    ESMO open·2022